Köhler & Milstein Research S.A. de C.V.

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Irritable bowel syndrome2 trials
• Obesity2 trials
• Asthma1 trial
• COPD1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• High blood pressure1 trial
• Osteoarthritis1 trial
• Rheumatoid arthritis1 trial
• Type 2 diabetes1 trial

Phase

• Phase 36 trials
• Phase 24 trials

Status

• Recruiting4 trials
• Not yet recruiting3 trials
• Completed2 trials
• Active, not recruiting1 trial

Lead sponsor

• Eli Lilly and Company8 trials
• Alfasigma S.p.A.1 trial
• Boehringer Ingelheim1 trial

Running trials

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

  Contact: Jesus Simon Campos (principal investigator)

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

  NCT07759245· Phase 2· Eli Lilly and Company· Source

  Contact: Carlos Colonia Cano (principal investigator)

• Recruiting

  A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

  NCT07545759· Phase 2· Eli Lilly and Company· Source

  Contact: Jose Alcocer Tamayo (principal investigator)

• Recruiting

  A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

  NCT07545772· Phase 2· Eli Lilly and Company· Source

  Contact: Jose Alcocer Tamayo (principal investigator)

• Recruiting

  A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

  NCT07219173· Phase 2· Eli Lilly and Company· Source

  Contact: Carlos Colonia Cano (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Jesus Simon Campos (principal investigator)

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

  NCT07153471· Phase 3· Eli Lilly and Company· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Irritable bowel syndrome2 recruiting
• Asthma1 recruiting
• COPD1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Eli Lilly and Company· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source